|
|
| Line 1: |
Line 1: |
| | | | |
| − | ==Annotated Information==
| |
| − | ===Name===
| |
| − | MHENCR:melanoma highly expressed competing endogenous lncRNA for miR-425 and miR-489
| |
| − |
| |
| − | ===Cellular Localization===
| |
| − | MHENCR is predominantly localized in the cytoplasm of melanoma cells.<ref name="ref1" />
| |
| − |
| |
| − | ===Function===
| |
| − | [[File:LncRNA MHENCR function.jpg|right|thumb|400px|'''The effects of MHENCR on melanoma cell proliferation, cell cycle and apoptosis'''<ref name="ref1" />.]]
| |
| − | In vivo, MHENCR can play a role in pro-growth and pro-metastasis.<ref name="ref1" />
| |
| − | MHENCR knockdown significantly inhibits melanoma cells proliferation, induces cell cycle arrest and apoptosis, and also attenuates melanoma cells migration. In addition, Statistically significant correlations are also observed between MHENCR expression and IGF1 and SPIN1 in melanoma tissues. MHENCR as a competitively endogenous RNA, which specifically bound to miR-425 and miR-489, can upregulate their target genes IGF1 and SPIN1 expression, and further activate PI3K-Akt pathway. <ref name="ref1" />
| |
| − |
| |
| − | ===Expression===
| |
| − | The expression of MHENCR is upregulated in melanoma tissues and further upregulated in later stage and metastatic lesions.
| |
| − | In addition, high expression of MHENCR is associated with poor prognosis of melanoma patients.<ref name="ref1" />
| |
| − |
| |
| − | ===Diseases===
| |
| − | Melanoma<ref name="ref1" />
| |
| − | ===Sequence===
| |
| − | >NR_132417.1 Homo sapiens melanoma highly expressed competing endogenous lncRNA for miR-425 and miR-489 (MHENCR), transcript variant 1, long non-coding RNA
| |
| − | <dnaseq>CAGCTCCTAACGCCGCAGGTTCCTCCTGGTCCCCGAGGCCCCCGGTCGGGCGTTGCCTGCCCCGCGCGGG
| |
| − | CGGCCGGGCCGAGGGACGATGGTCAGTGGACGGACGGCGCCAGGGAGCAGTGCCCACGCGCGGCAGGGCG
| |
| − | GTACCTTCAGGCCTCCAGAGGCTGGGGCTGGCTCTGTTGGCCTCTGTGCTGGGTTTCTTCCTCTGCACCG
| |
| − | CAGGACTGGCTCTCCTGACCTCTCCAGGTGTCATCGAACACCCTTGTGCTTGCTGTCACCCGCTGCCTGT
| |
| − | CTGCAGGATCCCGGATTCCGTATCAGGGGACCGAAATTAGTCGGAAAATAGGAAGCAGGTGCTCGCTTGG
| |
| − | ATGGAACCCTGACCCTGTGCTCACACTTGTAGGAGGAGGGCTCTGCAGGCCGCCTCCCGGAACGGGAGGT
| |
| − | TCCCAAGCCACTGCACTTCGGAGGGGCTGTAATTAGAGTTGCACATTCATTCAGTTCCCAGTAAAGTAGA
| |
| − | ACGTGCTCCAGCCAGTGAGGAAAAGGTGTTTTTAAAAATTAGATTGGCCGAGTGCGGTGGCTCATGCCTT
| |
| − | TTACCTCAACACTTTGGGAGACAAAGGTGGGAGGATCACCTGTGGCCAGGAGTTCAAGACCAGCCTGGGC
| |
| − | AACAGAGCCTGTCTCTGGGGAAGAATAAAAAAAAAAATTGAGCCTTTGTCAGTGCTACTATTTTATTATC
| |
| − | TGGTAAATATGAGAGGGTTCACGCGGTCTATGTGTGTCATTTATCTGAGTTTGCCTATCGTCACGTTTTG
| |
| − | GAAATAAATGTCAATAAAGTCGA</dnaseq>
| |
| − | ==Labs working on this lncRNA==
| |
| − | *Department of Burn and Plastic Surgery, The 253rd Hospital of PLA Hohhot, Inner Mongolia, China.
| |
| − | ==References==
| |
| − | <references>
| |
| − | <ref name="ref1">
| |
| − | Chen X, Dong H, Liu S, Yu L, Yan D, Yao X, Sun W, Han D, Gao G. Long noncoding
| |
| − | RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated
| |
| − | PI3K-Akt pathway. Am J Transl Res. 2017 Jan 15;9(1):90-102.
| |
| − | </ref>
| |
| − | </references>
| |
